Modifying effects of chemicals on the development of liver preneoplastic placental glutathione S-transferase positive foci in analbuminemic and Sprague-Dawley rats. 1993

J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
First Department of Pathology, Nagoya City University Medical School, Japan.

Nagase analbuminemic rats (NARs) were compared to the Sprague-Dawley (SD) stock in a medium-term assay system for hepatocarcinogenesis regarding their susceptibilities to the influence of chemicals on the development of glutathione S-transferase, placental form, positive (GST-P+) foci. Two weeks after initiation with diethylnitrosamine (DEN), the animals were exposed alternatively to 0.06% 3'-methyl-4-dimethyl-aminoazobenzene (3'-Me-DAB), 50 ppm DEN, 0.25% ethionine, 1% clofibrate, and 1% butylated hydroxyanisole (BHA) for a 6-wk period. Adequate controls included groups only initiated with DEN or treated with each test compound alone. For evaluation of the modifying potential of the chemicals, indices were generated by using the mean values obtained for number and area of GST-P+ foci after each treatment. Comparison between these indices suggests that SD rats were relatively more sensitive than NARs to the modifying effects of complete carcinogens (3'-Me-DAB and DEN). The strains were similarly-susceptible to the promoting influence of ethionine, a nongenotoxic carcinogen. The inhibitory influence of BHA was more intense in NARs, whereas in both strains clofibrate was associated to similarly reduced values for number and area of GST-P+ foci. The degree of susceptibility of each strain to the modifying influence of chemicals on foci development depended on the chemical agent investigated.

UI MeSH Term Description Entries
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D008297 Male Males
D008749 Methyldimethylaminoazobenzene A very potent liver carcinogen. MeDAB,3'-Methyl-4-dimethylaminoazobenzene,Dimethyl-p-(m-tolylazo)aniline,3' Methyl 4 dimethylaminoazobenzene
D010920 Placenta A highly vascularized mammalian fetal-maternal organ and major site of transport of oxygen, nutrients, and fetal waste products. It includes a fetal portion (CHORIONIC VILLI) derived from TROPHOBLASTS and a maternal portion (DECIDUA) derived from the uterine ENDOMETRIUM. The placenta produces an array of steroid, protein and peptide hormones (PLACENTAL HORMONES). Placentoma, Normal,Placentome,Placentas,Placentomes
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011922 Rats, Mutant Strains Rats bearing mutant genes which are phenotypically expressed in the animals. Mutant Strains Rat,Mutant Strains Rats,Rat, Mutant Strains,Strains Rat, Mutant,Strains Rats, Mutant
D002083 Butylated Hydroxyanisole Mixture of 2- and 3-tert-butyl-4-methoxyphenols that is used as an antioxidant in foods, cosmetics, and pharmaceuticals. Butylhydroxyanisole,(1,1-Dimethylethyl)-4-methoxyphenol,AMIF-72,BHA,Butyl Methoxyphenol,Embanox,Nipantiox 1-F,Tenox BHA,AMIF 72,AMIF72,Hydroxyanisole, Butylated,Methoxyphenol, Butyl,Nipantiox 1 F,Nipantiox 1F
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl
D004052 Diethylnitrosamine A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. Nitrosodiethylamine,N-Nitrosodiethylamine,N Nitrosodiethylamine

Related Publications

J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
June 1994, Japanese journal of cancer research : Gann,
J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
October 1990, Cancer letters,
J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
October 1991, Carcinogenesis,
J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
February 1987, Japanese journal of cancer research : Gann,
J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
January 1999, Carcinogenesis,
J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
July 1989, Japanese journal of cancer research : Gann,
J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
January 1988, Japanese journal of cancer research : Gann,
J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
May 2005, Cancer letters,
J L de Camargo, and H Tsuda, and M Asamoto, and Y Tagawa, and S Wada, and S Nagase, and N Ito
January 1994, Teratogenesis, carcinogenesis, and mutagenesis,
Copied contents to your clipboard!